Data from Covid 19 program expected any day now this could push this low float stock toward $10 fast . One of the CHEAÜEST biotechs on Nasdaq .
Market Cap $29 Million /Shares Out 12.3 Million / 2x Phase 3 Assets / 2x NDA (Re)submission expected during next 6-9 months / readout from Covid 19 trial expected during this month if positive Company wil start Phase 2/3 in 1H 2021 / Strong Insider & Institutional Ownership = Low float stock with MASSIVE Upside Potential which could hit $20 and more on Drug approvals and positive results (more infos below) .GL
Acer Therapeutics (ACER)
Market Cap : $29 Million
Cash $7 Million
Price $2.40
Shares Out 12.3 Million
Latest Presentation
acertx.com
These 2 Penny Stocks Are Poised for a Massive Rally, Says Roth Capital..
finance.yahoo.com
 |
